Chief Medical Officer at SomaLogic to Lead Session at CHI’s Phase III Clinical Trials Forum

PRLog (Press Release) - Jan. 3, 2012 - Cambridge Healthtech Institute (CHI) announces the addition of Stephen A. Williams, M.D., Ph.D., CMO, SomaLogic, Inc., to its speaker roster at the inaugural Phase III Clinical Trials: Strategic Decisions for Successful Drugs forum to be held on March 12-13, 2012 at the Crowne Plaza Hotel Downtown, Philadelphia, PA.

Dr. Williams will present on evidentiary standards for surrogate endpoints, genetic testing & CDx. His talk is scheduled for Tuesday, March 13 at 11:15 a.m. How can we explain, understand and manage the perceived differences in evidentiary standards viewed as reasonable by Pharma and regulatory authorities? This talk will use examples such as suicidality, cardiovascular risk and K-ras, while providing evidence from recent case studies and standards set by the FDA. His talk is part of the phase II to phase III transition: trial designs and strategies session.

Early registration discounts are available until January 6, 2012. To view the agenda and to register, please visit http://www.healthtech.com/ph3.

To inquire about sponsoring and/or exhibiting, contact Carol Dinerstein, 781-972-5471, dinerstein@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com